Apnimed
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
39 JFK St Fl 4, Cambridge, Massachusetts...Phone Number
(877) 276-4633Website
www.apnimed.comRevenue
$38.5 MillionIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
3
3
1
1
2
About Apnimed
Apnimed is a clinicalstage biopharmaceutical company focused on discovering, developing and commercialising novel oral therapies for sleeprelated breathing diseases, especially obstructive sleep apnea (OSA). Its lead investigational drug candidate, AD109, is designed to address the underlying neuromuscular dysfunction that contributes to airway collapse during sleep, with the goal of offering a simpler treatment option to devices or surgery. The company emerged from research and aims to expand effective diagnosis and treatment reach for people living with OSA and similar conditions.Apnimed is seen as an innovative clinicalstage biotech in sleep medicine, generating strategic collaborations and funding to support latestage clinical development and potential regulatory submissions.Explore more
Apnimed Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Apnimed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Apnimed
Product Launch: Get notified when Apnimed launches new products
Funding: Get notified immidiatlly once Apnimed has new funding data
Click to see if Apnimed had a recent Job posting/layoffs
Earning: See what the market has to say on Apnimed recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if Apnimed has recently received funding, and reach out quickly before it becomes old news!
Apnimed, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Apnimed is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Apnimed as Masked Content
Find 3 more new buyers
Compare Similar Companies to Apnimed
Compare insights from companies similar to Apnimed, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Apnimed is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Apnimed is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Apnimed.
Apnimed financials insights
Gather financial insights about Apnimed, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$15M
2021
Series B
$25M
2023
Series C
$142.3M
2025
Debt
$23M
2026
Private Equity
$25M
Debt
$150M
Apnimed Tech Stack
A closer look at the technologies used by Apnimed
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Lateral Move
Executive Move
Executive Moves, Lateral Move, Board of Directors
Facilities Relocation / Expansion
Apnimed is planning to move offices in August 2026. The move will impact approximately 83 employees at the existing office located at 39 John F. Kennedy St., 4th Floor, Cambridge, MA.
Facilities Relocation/Expansion
Funding
Funding
Apnimed News & Media
Apnimed Announces FDA Acceptance of New Drug Application for AD109, An Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea (OSA)
The FDA assigned a PDUFA target action date of February 28, 2027 If approved, AD109 has the potential to become the first oral pharmacologic therapy designed to address the neuromuscular root cause of upper airway collapse for the millions of people living with OSA CAMBRIDGE, Mass., July...Apnimed Strengthens Leadership Team with Appointments of Industry Veterans Michael Kelly as Chief Financial Officer and Steven Spector as Chief Legal Officer and Head of Corporate Affairs
New Chief Financial Officer and Chief Legal Officer and Head of Corporate Affairs follow recent appointment of Kevin Lind as Chief Executive Officer, in a planned succession strategy preparing Apnimed for its next stage of growth Michael Kelly brings more than 25 years of healthcare...Apnimed Announces Upcoming Oral Presentation at SLEEP 2026 to Highlight Pooled Phase 3 Data for AD109 in Obstructive Sleep Apnea
CAMBRIDGE, Mass., June 10, 2026 /PRNewswire/ -- Apnimed, Inc., a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that six...
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Apnimed
Sign Up For FreeTo access detailed company insights
Apnimed is a clinicalstage biopharmaceutical company focused on discovering, developing and commercialising novel oral therapies for sleeprelated breathing diseases, especially obstructive sleep apnea (OSA). Its lead investigational drug candidate, AD109, is designed to address the underlying neuromuscular dysfunction that contributes to airway col... Read More
